¼¼°èÀÇ ºÎÀΰú Ä¡·áÁ¦ ½ÃÀå
Gynecology Drugs
»óǰÄÚµå : 1757627
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 386 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ºÎÀΰú Ä¡·áÁ¦ ½ÃÀåÀº 2030³â±îÁö 81¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 60¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ºÎÀΰú Ä¡·áÁ¦ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 5.3%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 81¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ºñÈ£¸£¸ó ¿ä¹ýÀº CAGR 4.1%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 48¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. È£¸£¸ó ¿ä¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ÀÇ CAGR·Î 7.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ºÎÀΰú Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 16¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 8.2%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.7%¿Í 5.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ "ºÎÀΰú Ä¡·áÁ¦" ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

ºÎÀΰú Ä¡·áÁ¦°¡ ¿©¼º °Ç°­ÄɾîÀÇ Áß½ÉÀÌ µÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

ºÎÀΰú Ä¡·áÁ¦´Â ¿ù°æ Àå¾Ö, È£¸£¸ó ±ÕÇü Àå¾Ö, Àڱ󻸷Áõ, ºÒÀÓ, °»³â±â Áõ»ó, ºÎÀΰú °¨¿°¿¡ À̸£±â±îÁö ¿©¼º »ý½Ä °Ç°­¿¡ ƯÀ¯ÇÑ ´Ù¾çÇÑ Áõ»ó¿¡ ´ëÀÀÇϸç ÇコÄɾîÀÇ ±âº»ÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¿©¼º °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ °ú°Å¿¡´Â ³«ÀÎÂïÈ÷°Å³ª Á¦´ë·Î Ä¡·á¹ÞÁö ¸øÇß´ø ¹®Á¦µé¿¡ ´ëÇØ Àû±ØÀûÀ¸·Î ÀÇ·áÀû °³ÀÔÀ» ¿äûÇϴ ȯÀÚµéÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®È­Àû º¯È­´Â ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º Áõ°¡¿Í ÇÔ²² Ç¥ÀûÈ­µÈ ÀǾàǰ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ºÎÀΰú Àü¹® Ŭ¸®´ÐÀÇ È®´ë¿Í 1Â÷ Áø·á¿¡ ¿©¼º °Ç°­À» ÅëÇÕÇÏ´Â °ÍÀº ¿¬·É´ë¿Í Áö¿ª¿¡ °ü°è¾øÀÌ ´õ ºü¸¥ Áø´Ü°ú ÀϰüµÈ Ä¡·á¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Çõ½ÅÀº ºÎÀΰú ÁúȯÀÇ Ä¡·á ¿É¼ÇÀ» ¾î¶»°Ô À籸¼ºÇϰí Àִ°¡?

ºÎÀΰú Ä¡·áÁ¦ ½ÃÀåÀº º¸´Ù È¿°úÀûÀÌ°í ³»¾à¼ºÀÌ ¿ì¼öÇÏ¸ç °³ÀÎÈ­µÈ Ä¡·á¹ýÀÇ °³¹ß·Î ºü¸£°Ô ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. È£¸£¸ó ´ëü¿ä¹ý(HRT), ¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü Á¶ÀýÁ¦(SERM), °æ±¸ ÇÇÀÓ¾àÀº ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» °³¼±Çϰí, ¼­¹æÇü Á¤Á¦, Áú ¸µ, ÁÖ»çÁ¦ µî ÆíÀǼº Áß½ÉÀÇ Åõ¿© ¹æ¹ýÀ¸·Î °³¼±µÇ°í ÀÖ½À´Ï´Ù. °»³â±â, Àڱ󻸷Áõ µîÀÇ Áõ»ó¿¡ ´ëÇÑ ºñÈ£¸£¸óÁ¦´Â ºÎÀÛ¿ë¿¡ ´ëÇÑ ¿ì·Á·Î ´ëü¾àÀ» ã´Â ¿©¼ºµé »çÀÌ¿¡¼­ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ÇÑÆí, ºÎÀΰú ¾ÏÀ̳ª ¸¸¼º °ñ¹Ý ¿°Áõ¼º Áúȯ¿¡ ´ëÇØ´Â Ç¥Àû »ý¹°Á¦Á¦³ª ¸é¿ª¿ä¹ýÀÌ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. Ä¡·á ¼øÀÀµµ ¹× ¿ø°Ý ¸ð´ÏÅ͸µ°ú ¿¬µ¿µÈ »ý¸® ÃßÀû ¾Û°ú °°Àº µðÁöÅÐ °Ç°­ ÅøÀÇ ÅëÇÕÀº Ä¡·á ¼º°ú¿Í ¼øÀÀµµ¸¦ ´õ¿í Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖ´Â Áö¿ª°ú ÁÖ¿ä ÀÌÇØ°ü°èÀÚ´Â?

ºÏ¹Ì°¡ ºÎÀΰú Ä¡·áÁ¦ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÁַΠźźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº Áø´ÜÀ², ÁÖ¿ä Á¦¾à Çõ½Å°¡µéÀÇ Á¸Àç¿¡ ±âÀÎÇÕ´Ï´Ù. À¯·´ÀÌ ±× µÚ¸¦ ÀÕ°í ÀÖÀ¸¸ç, À¯·´°ú ¹Ì±¹ ±¹°¡µéÀÇ °­·ÂÇÑ ¼ö¿ä´Â ±¹°¡Àû ÀÇ·á ÇÁ·Î±×·¥ ¹× ¿©¼º Àü¿ë Äɾ ´ëÇÑ ³ë·Â Áõ°¡·Î ÀÎÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Àεµ, Áß±¹, ÀϺ» µî ½ÃÀåÀÌ µµ½ÃÈ­, Áß»êÃþÀÇ ÀÇ·á Á¢±Ù¼º Áõ°¡, ÀÓ»êºÎ ¹× »ý½Ä °Ç°­¿¡ ´ëÇÑ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î ¼ö¿ä Áõ°¡¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. Á¦¾àȸ»ç, »êºÎÀΰú ÀÇ»ç, °³¾÷ÀÇ, ¿©¼º °Ç°­ ¿ËÈ£ ´Üü´Â ¸ðµÎ ÀÌ È®´ëµÇ´Â ½ÃÀåÀÇ ÁÖ¿ä ÀÌÇØ°ü°èÀÚÀÔ´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·á¿Í ¿Â¶óÀÎ ¾à±¹ÀÇ µîÀåÀ¸·Î ÀǾàǰ¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í, ÀÇ·á ÇýÅÃÀÌ ºÎÁ·ÇÑ Áö¿ªÀÇ Ä¡·á À庮ÀÌ ³·¾ÆÁö°í ÀÖ½À´Ï´Ù.

ºÎÀΰú Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ºÎÀΰú Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ¿©¼º °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Áø´Ü ¹× Ä¡·á ½Ã¼³¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë, »ý½Ä ¹× È£¸£¸ó Áúȯ¿¡ ´ëÇÑ Ç¥Àû Ä¡·á Æ÷Æ®Æú¸®¿À Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀü, ÀڱñÙÁ¾ ¹× ´Ù³¶¼º³­¼ÒÁõÈıº(PCOS)°ú °°Àº ¹ÌÃæÁ· Ä¡·á ÀûÀÀÁõ¿¡ ´ëÇÑ »õ·Î¿î Ä¡·áÁ¦ÀÇ µµÀÔ, ºÒÀÓ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ½ÃÀåÀ» ´õ¿í Ȱ¼ºÈ­½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºÎÀΰú ¾Ï¿¡ ´ëÇÑ Á¾¾çÇп¡ ´ëÇÑ ÀǾàǰ ¿¬±¸°³¹ß ÅõÀÚ, È£¸£¸ó ¿ä¹ý ¹× ÇÇÀÓ¿¡ ´ëÇÑ À¯¸®ÇÑ ±ÔÁ¦ Áö¿ø ¹× º¸Çè Àû¿ëÀÌ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªµ¿¼ºÀ¸·Î ÀÎÇØ ºÎÀΰú Ä¡·áÁ¦´Â ±¤¹üÀ§ÇÑ Á¦¾à »ê¾÷¿¡¼­ Áß¿äÇÑ ¼ºÀå ºÎ¹®À¸·Î º¯¸ðÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Ä¡·áÁ¦(ºñÈ£¸£¸ó ¿ä¹ý, È£¸£¸ó ¿ä¹ý), ÀûÀÀÁõ(ÇÇÀÓ ÀûÀÀÁõ, ¿©¼º ºÒÀÓ ÀûÀÀÁõ, Æó°æ ÈÄ Àå¾Ö ÀûÀÀÁõ, ´Ù³¶¼º³­¼ÒÁõÈıº ÀûÀÀÁõ, °ñ´Ù°øÁõ ÀûÀÀÁõ, Àڱ󻸷Áõ ÀûÀÀÁõ, ±âŸ ÀûÀÀÁõ), À¯Åë ä³Î(¼Ò¸Å ¾à±¹, º´¿ø ¾à±¹, ¿Â¶óÀÎ À¯Åë ä³Î)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 44»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Gynecology Drugs Market to Reach US$8.1 Billion by 2030

The global market for Gynecology Drugs estimated at US$6.0 Billion in the year 2024, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Non-Hormonal Therapy, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Hormonal Therapy segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 8.2% CAGR

The Gynecology Drugs market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global "Gynecology Drugs" Market - Key Trends & Drivers Summarized

Why Are Gynecology Drugs Becoming Central to Women’s Health Management?

Gynecology drugs are a fundamental part of the healthcare landscape, addressing a broad spectrum of conditions specific to women’s reproductive health-from menstrual disorders, hormonal imbalances, and endometriosis to infertility, menopause symptoms, and gynecological infections. As awareness surrounding women’s health issues continues to grow globally, more patients are actively seeking medical intervention for concerns that were previously stigmatized or undertreated. This cultural shift, along with increasing healthcare access, is driving demand for targeted pharmaceutical solutions. The expansion of gynecology-focused clinics and integration of women’s health into primary care pathways are contributing to earlier diagnosis and more consistent treatment across age groups and geographies.

How Is Innovation Reshaping Therapeutic Options for Gynecological Conditions?

The gynecology drugs market is evolving rapidly with the development of more effective, better-tolerated, and personalized therapeutic options. Hormone replacement therapies (HRT), selective estrogen receptor modulators (SERMs), and oral contraceptives are being reformulated with improved safety profiles and convenience-focused delivery methods, such as extended-release tablets, vaginal rings, and injectables. Non-hormonal drugs for conditions like menopause and endometriosis are gaining popularity among women seeking alternatives due to side effect concerns. Meanwhile, targeted biologics and immunotherapies are being explored for gynecologic cancers and chronic pelvic inflammatory diseases. The integration of digital health tools-like menstrual tracking apps linked to treatment adherence and remote monitoring-is further improving care outcomes and compliance.

Where Is Market Demand Accelerating and Who Are the Key Stakeholders?

North America dominates the gynecology drugs market, largely due to robust healthcare infrastructure, high diagnostic rates, and the presence of major pharmaceutical innovators. Europe follows closely, with strong demand in Western nations supported by national health programs and a rising focus on women-specific care initiatives. In Asia-Pacific, markets such as India, China, and Japan are witnessing increasing demand, fueled by urbanization, growing middle-class access to healthcare, and greater attention to maternal and reproductive health. Pharmaceutical companies, gynecologists, general practitioners, and women’s health advocacy groups are all key stakeholders in this expanding market. Additionally, the rise of telemedicine and online pharmacies is improving drug accessibility and reducing barriers to treatment in underserved regions.

What Factors Are Powering the Growth of the Gynecology Drugs Market?

The growth in the gynecology drugs market is driven by several factors, including increased awareness of women’s health issues, expanded access to diagnostic and treatment facilities, and a growing portfolio of targeted therapies for reproductive and hormonal conditions. Technological advances in drug delivery systems, the introduction of novel therapeutics for underserved indications such as uterine fibroids and polycystic ovary syndrome (PCOS), and rising demand for fertility treatments are further fueling the market. Additionally, pharmaceutical R&D investments in oncology for gynecological cancers, along with favorable regulatory support and insurance coverage for hormonal therapies and birth control, are contributing to sustained market expansion. These dynamics are transforming gynecology drugs into a key growth segment within the broader pharmaceutical industry.

SCOPE OF STUDY:

The report analyzes the Gynecology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutics (Non-Hormonal Therapy, Hormonal Therapy); Indication (Contraception Indication, Female Infertility Indication, Postmenopausal Disorders Indication, Polycystic Ovary Syndrome Indication, Osteoporosis Indication, Endometriosis Indication, Other Indications); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â